Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Results announcement for the third quarter 2013
GSK announces Q3 core EPS growth of 16% and dividend of 19p
-
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
ViiV announced submission application in the US for STR combining dolutegravir, abacavir and lamivudine for treatment of people with HIV-1.
-
Regulatory update – GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
GSK and Genmab A/S announced today the submission of a supplemental Biologics License Application to the US Food and Drug Administration
-
Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children
Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate.
-
Regulatory update – GSK and Genmab announce European submission to regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
GSK & Genmab A/S announced submission of Marketing Authorisation for Arzerra in combination with alkylator-based therapy, for CLL patients
-
GlaxoSmithKline reaches agreement with Aspen to divest thrombosis brands and related manufacturing site for £0.7 billion
Divestment supports strategic focus and delivery of pipeline.
-
GSK and Barclays form partnership to increase access to healthcare and promote economic development in Zambia
GSK & Barclays have formed partnership which aims to increase affordable healthcare for people in Zambia, improving economic conditions
-
GSK receives marketing authorisation from the European Commission for additional Revolade™
GSK announced that the EC has granted Revolade™ as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection.
-
RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma
GSK & THRX announced that JMHLW has approved RELVAR™ ELLIPTA™ for the treatment of bronchial asthma.
-
GSK and Prosensa announce primary endpoint not met in Phase III study of drisapersen in patients with Duchenne Muscular Dystrophy
GSK & Prosensa announced that Phase III clinical study of drisapersen, treatment for DMD did not meet the primary endpoint.
-
GSK signs a multi-year agreement with BARDA to supply the US government with anthrax treatment
GlaxoSmithKline (GSK) plc today announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA).
-
RELVAR™ ELLIPTA™ receives positive opinion from the CHMP in Europe for the treatment of asthma and COPD
GSK and Theravance, Inc. has issued a positive opinion for fluticasone furoate/vilanterol under the proposed brand name RELVAR™ ELLIPTA™.
-
GSK receives Priority Review from FDA for dabrafenib/trametinib combination in metastatic melanoma
GSK announced that the FDA has granted Priority Review designation to the use of Tafinlar® & Mekinist® for the treatment of melanoma
-
GSK statement in response to patent ruling reversal on Lovaza
the Court of Appeals for the Federal Circuit has ruled against Pronova Biopharma Norge AS in its patent litigation regarding Lovaza®
-
FDA grants GSK and Genmab’s Arzerra® (ofatumumab) Breakthrough Therapy designation for previously untreated chronic lymphocytic leukaemia
GSK & Genmab A/S announced today that FDA has granted Breakthrough Therapy designation for Arzerra® (ofatumumab) with chlorambucil for CLL
-
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1
ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study.
-
FDA Advisory Committee recommends approval in US of umeclidinium/vilanterol for the treatment of COPD
GSK & THRX announced that the PADAC voted 11/2 Yes/No for the efficacy & safety of umeclidinium/ vilanterol, treatment of COPD
-
GSK reaches agreement to divest Lucozade and Ribena for £1.35 billion
GSK today announced it has reached agreement to sell its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd.
-
The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial
In line with IDMC unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed.
-
GSK receives marketing authorisation from the European Commission for Tafinlar™
GSK announced today that the European Commission has granted marketing authorisation for Tafinlar™ (dabrafenib).
